Iran threatened to attack the military bases of the United States in the Middle East in retaliation for the unprecedented American strikes against Iranian nuclear sites, raising fears of an output beyond control of the region. These strikes have targeted an underground site for enriching uranium in Fordo, as well as installations in Ispahan and Natanz, where the extent of the damage remains to be evaluated.
“The world holds its breath while waiting to see how Iran will react,” warned Ipek Ozkardeskaya in a comment. According to Swissquote analyst, many observers “remain optimistic that Iran will avoid large -scale reprisals” in order to protect its own oil industry and its hydrocarbon exports to China. “It will be difficult for Iran to completely close the Strait of Ormuz for an extended period due to the presence of the 5the Fleet of the American Navy in Bahrain, “said RBC Capital Markets experts.
After blazing in the night, the prices of black gold resumed. In the morning, Brent still increased by 0.6% to $ 77.48 and its American counterpart WTI gained as much at $ 74.29.
Decrendy stars
Shortly before 9:10 am on the Swiss Stock Exchange, the SMI star index fell 0.41% to 11,823.13 points, after closing on Friday on a stable note. The SLI abandoned 0.44% at 1931.63 points and the SPI lost 0.32% to 16,395.21 points.
Almost all of the star values ​​seem red, with the exception of Givaudan (+0.2%), UBS (+0.2%) and Logitech (+0.1%). At the other end of the table were Holcim (-46.6%), Sonova (-1.4%) and Swiss Re (-1.2%).
While the building materials giant, relieved of its North American activities, displayed a technical fall, its North American emanation Amrize was negotiated at 44.98 francs, below its reference price of 46.08 francs. Vontobel analysts started the coverage of Amrize with a recommendation to “Hold” and a price target at 50 francs.
The Zurich reinsurer suffered a lowering of recommendation to “Underweight”, of “Equal Weight” previously, by analysts of Morgan Stanley.
Roche (-1.0%) reversed the positive pre-brass trend. The pharmaceutical giant has made the stall of an experimental treatment of its Japanese Chugai subsidiary against hemophilia A, on the occasion of the annual congress of the International Association against thrombosis and coagulation disorders.
The third heavy goods vehicle Nestlé (-0.2%) also weighed on the SMI.
On the extended market, Idorsia (+6.8%) was acclaimed by the speakers. The laboratory, in delicacy with its finances, takes advantage of the homologation in China of its Quviviq sleeping pill to rebuild the terms of the distribution partnership in the Middle Kingdom with Simcere Pharmaceutical. (Awp)
